• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Incyte Corp (INCY)

Common Shares
Sell: $119.50|Buy: $125.00|Change: 3.59 (3.07%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Address

1801 Augustine Cut-Off
Wilmington
DE
USA
19803

Telephone

+1 302 498-6700

Website

https://www.incyte.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Incyte Corp Third Quarter Earnings Conference Call for 20272027-10-29T08:00:00
Incyte Corp Third Quarter Earnings Results for 20272027-10-29T00:00:00
Incyte Corp Second Quarter Earnings Conference Call for 20272027-07-28T08:00:00
Incyte Corp Second Quarter Earnings Results for 20272027-07-28T07:00:00
Incyte Corp Annual General Meeting for 20272027-06-08T10:00:00
Incyte Corp First Quarter Earnings Conference Call for 20272027-04-28T08:00:00
Incyte Corp First Quarter Earnings Results for 20272027-04-28T07:00:00
Incyte Corp Fourth Quarter Earnings Conference Call for 20262027-02-10T08:00:00
Incyte Corp Fourth Quarter Earnings Results for 20262027-02-10T07:00:00
Incyte Corp Annual Report for 20262027-02-10T00:00:00
Incyte Corp Third Quarter Earnings Conference Call for 20262026-10-29T08:00:00
Incyte Corp Third Quarter Earnings Result for 20262026-10-29T00:00:00
Investor Event2026-10-26T14:30:00

Previous key dates

NameKey Date
Incyte Corp Third Quarter Earnings Conference Call for 20262026-10-29T08:00:00
Incyte Corp Third Quarter Earnings Result for 20262026-10-29T00:00:00
Investor Event2026-10-26T14:30:00
Morgan Stanley 24th Annual Global Healthcare Conference2026-09-16T12:20:00
Cantor Global Healthcare Conference 20262026-09-10T09:45:00
21st Annual Wells Fargo Healthcare Conference2026-09-09T11:00:00
Incyte Corp Second Quarter Earnings Conference Call for 20262026-07-28T08:00:00
Incyte Corp Second Quarter Earnings Results for 20262026-07-28T07:00:00
Goldman Sachs 47th Annual Global Healthcare Conference2026-06-09T08:40:00
Incyte Corp Annual General Meeting for 20262026-06-08T10:00:00
Incyte Conference Call and Webcast2026-06-08T08:00:00
RBC 2026 Global Healthcare Conference2026-05-19T10:30:00
BofA Securities 2026 Health Care Conference2026-05-13T13:40:00
Incyte Corp First Quarter Earnings Conference Call for 20262026-04-28T08:00:00
Incyte Corp First Quarter Earnings Results for 20262026-04-28T07:00:00
Barclays 28th Annual Global Healthcare Conference2026-03-11T08:30:00
Leerink Partners 2026 Global Healthcare Conference2026-03-10T09:20:00
TD Cowen 46th Annual Health Care Conference2026-03-02T10:30:00
Incyte Corp Fourth Quarter Earnings Conference Call for 20252026-02-10T08:00:00
Incyte Corp Fourth Quarter Earnings Results for 20252026-02-10T07:00:00
Incyte Corp Annual Report for 20252026-02-10T00:00:00
44th Annual J. P. Morgan Healthcare Conference2026-01-12T08:15:00
Investor Event - ASH 20252025-12-07T11:00:00
8th Annual Evercore Healthcare Conference2025-12-03T13:20:00
Citi’s 2025 Global Healthcare Conference2025-12-02T11:15:00
Jefferies Global Healthcare Conference2025-11-18T11:00:00
Guggenheim Annual Healthcare Innovation Conference2025-11-10T10:00:00
Incyte Corp Third Quarter Earnings Conference Call for 20252025-10-28T08:00:00
Incyte Corp Third Quarter Earnings Results for 20252025-10-28T07:00:00
Incyte Investor Event- ESMO 20252025-10-19T19:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.